Cowen Upgrades Ionis Pharmaceuticals (IONS) to Outperform

December 15, 2020 5:31 AM EST
Get Alerts IONS Hot Sheet
Price: $37.48 +0.94%

Rating Summary:
    8 Buy, 10 Hold, 2 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 15 | Down: 17 | New: 13
Trade Now! 
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Cowen analyst Yaron Werber upgraded Ionis Pharmaceuticals (NASDAQ: IONS) from Market Perform to Outperform.

The analyst comments "IONS’ deep internal pipeline is largely overlooked by investors and includes highly differentiated drugs in indications with high unmet need. We believe management’s new focus on the internal pipeline is a key strategy that will establish IONS’ long-term revenue growth driven by its wholly owned pipeline. Multiple data readouts in ’21-‘22 should drive 6+ new drug launches by ‘26."

For an analyst ratings summary and ratings history on Ionis Pharmaceuticals click here. For more ratings news on Ionis Pharmaceuticals click here.

Shares of Ionis Pharmaceuticals closed at $47.83 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Upgrades

Related Entities

Cowen & Co